Previous 10 | Next 10 |
I held on to my shares of Gilead Sciences (NASDAQ: GILD) for a long time. When sales for the big biotech's hepatitis C franchise sank a few years ago, pulling the stock down along the way, I stayed the course. When Gilead's seemingly promising nonalcoholic steatohepatitis (NASH) candidate s...
Gilead Sciences (NASDAQ: GILD) navigated the coronavirus market crash better than most. At one point, the biotech's antiviral drug, Veklury (remdesivir), was considered one of the most promising potential treatments for COVID-19. In May, the U.S. Food and Drug Administration (FDA) granted Ve...
Jefferies downgraded Belgian biotech company, Galapagos ( GLPG -1.8% ) to Hold from Buy. More news on: Galapagos NV, Healthcare stocks news, Stocks on the move, Read more ...
Gilead Sciences (NASDAQ: GILD ) watched its share price go down by almost 5% as a result of an unexpected adverse ruling by the FDA against Filgotinib. Filgotinib, a drug created in collaboration with Galapagos (NASDAQ: GLPG ) caused that company's share price to drop by 25%, a stock that Gi...
G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA G1 Therapeutics Inc. ( GTHX ) reported that the FDA has accepted its New Drug Application of its lead drug candidate, Trilaciclib. The FDA has given Priority Review status to the NDA, and the PDUFA action date has ...
Gainers: Allied Esports Entertainment (NASDAQ: AESE ) +94% . More news on: Allied Esports Entertainment Inc., Momenta Pharmaceuticals, Inc., Hudson Ltd., Stocks on the move, , Read more ...
Shares of Galapagos (NASDAQ: GLPG) were crashing 24.6% lower as of 11:14 a.m. EDT on Wednesday. The big drop came after the biotech's partner, Gilead Sciences (NASDAQ: GILD) , announced that it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA...
Galapagos NV (NASDAQ: GLPG ) and licensee Gilead Sciences (NASDAQ: GILD ) are down 29% and 7% , respectively, premarket on the heels of a CRL from the FDA regarding GILD's marketing application for filgotinib for rheumatoid arthritis (RA). The agency's request for mor...
Galapagos NV (NASDAQ: GLPG ) reports that collaboration partner and licensee Gilead Sciences (NASDAQ: GILD ) received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval of filgotinib for the treatment of moderate-to-severe rheumatoid ar...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...